SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (16989)3/9/1998 7:38:00 PM
From: Mudcat  Read Replies (2) | Respond to of 32384
 
Henry:

In reading the press release about the extension to select a drug from Lilly, I am confused. The release states if Lgnd doesn't select a drug, Lily buys $20M in Lgnd shares at 20% premium (Lgnd will make approx $3M plus stock dilution). If Lgnd selects a drug then they get the drug but must pay Lilly $20M in stock also? I don't remember ever reading this part before. It looks like Lilly makes out big regardless of Lgnd's decision.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News